Publication: Direct medical cost of thai pediatric asthma management: A pilot study
Issued Date
2015-12-01
Resource Type
ISSN
22288694
0125877X
0125877X
Other identifier(s)
2-s2.0-84955279364
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.33, No.4 (2015), 296-300
Suggested Citation
Pongtong Puranitee, Wasu Kamchaisatian, Wiparat Manuyakorn, Soamarat Vilaiyuk, Orawin Laecha, Oraluck Pattanaprateep, Suwat Benjaponpitak Direct medical cost of thai pediatric asthma management: A pilot study. Asian Pacific Journal of Allergy and Immunology. Vol.33, No.4 (2015), 296-300. doi:10.12932/AP0494.33.4.2015 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36042
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Direct medical cost of thai pediatric asthma management: A pilot study
Other Contributor(s)
Abstract
© 2009 is a Digital Portal of health science journals in Thailand. Background: The prevalence of asthma in Bangkok increased steadily over the last couple of decades and warrants an assessment of the costs associated with its treatment, particularly in the case of children. Objective: To estimate the direct medical costs of asthma care in children at the Allergy unit of the Department of Pediatrics, Ramathibodi hospital. Methods: In this retrospective study, we included asthmatic children aged less than 20 year-old having visited the allergy unit at least 4 times in 12 months between January and December, 2011. Cost data, retrieved from the allergy unit electronic database included billing invoices of inpatient care, outpatient and emergency room visits. From this dataset we estimated drug costs, physician and nursing services, diagnostic tests and procedures, supplies and room charges, and assessed an overall asthma-related direct medical cost. Results: Ninety-seven asthmatic children (aged 11.5 ± 3.7 years) were included in the study. Annual median direct medical cost was 8,537.9 Baht or 278 USD per patient. Annual direct medical cost was the highest in patients younger than 5 years old (p < 0.001). Moreover, expenses of patients who had at least one exacerbation increased significantly compared to patients without exacerbation (p = 0.02). Furthermore, direct medical cost was the highest when patients had exacerbation requiring hospitalization (p = 0.03). Conclusions: Cases of patients having asthma exacerbation or being diagnosed with asthma before 5 years of age were associated with higher treatment expenses. Policies developed to achieve asthma control and prevention should identify young children and patients presenting risk factors for asthma exacerbation as high risk groups deserving particular attention.